» Articles » PMID: 26716032

Prognostic Value of Stromal Decorin Expression in Patients with Breast Cancer: a Meta-analysis

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2015 Dec 31
PMID 26716032
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Numbers of studies have investigated the biological functions of decorin (DCN) in oncogenesis, tumor progression, angiogenesis and metastasis. Although many of them aim to highlight the prognostic value of stromal DCN expression in breast cancer, some controversial results still exist and a consensus has not been reached until now. Therefore, our meta-analysis aims to determine the prognostic significance of stromal DCN expression in breast cancer patients.

Methods: PubMed, EMBASE, the Web of Science and China National Knowledge Infrastructure (CNKI) databases were searched for full-text literatures met out inclusion criteria. We applied the hazard ratio (HR) with 95% confidence interval (CI) as the appropriate summarized statistics. Q-test and I(2) statistic were employed to estimate the level of heterogeneity across the included studies. Sensitivity analysis was conducted to further identify the possible origins of heterogeneity. The publication bias was detected by Begg's test and Egger's test.

Results: There were three English literatures (involving 6 studies) included into our meta-analysis. On the one hand, both the summarized outcomes based on univariate analysis (HR: 0.513; 95% CI: 0.406-0.648; P<0.001) and multivariate analysis (HR: 0.544; 95% CI: 0.388-0.763; P<0.001) indicated that stromal DCN expression could promise the high cancer-specific survival (CSS) of breast cancer patients. On the other hand, both the summarized outcomes based on univariate analysis (HR: 0.504; 95% CI: 0.389-0.651; P<0.001) and multivariate analysis (HR: 0.568; 95% CI: 0.400-0.806; P=0.002) also indicated that stromal DCN expression was positively associated with high disease-free survival (DFS) of breast cancer patients. No significant heterogeneity or publication bias was observed within this meta-analysis.

Conclusions: The present evidences indicate that high stromal DCN expression can significantly predict the good prognosis in patients with breast cancer. The discoveries from our meta-analysis have better be confirmed in the updated review pooling more relevant investigations in the future.

Citing Articles

A comprehensive genome-based analysis identifies the anti-cancerous role of the anoikis-related gene ADH1A in modulating the pathogenesis of breast cancer.

Chen C, Guo S, Chai W, Yang J, Yang Y, Chen G Mol Genet Genomics. 2024; 299(1):108.

PMID: 39531174 DOI: 10.1007/s00438-024-02200-y.


Decorin (DCN) Downregulation Activates Breast Stromal Fibroblasts and Promotes Their Pro-Carcinogenic Effects through the IL-6/STAT3/AUF1 Signaling.

Aljagthmi W, Alasmari M, Daghestani M, Al-Kharashi L, Al-Mohanna F, Aboussekhra A Cells. 2024; 13(8.

PMID: 38667295 PMC: 11049637. DOI: 10.3390/cells13080680.


Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.

Mondal D, Xie C, Pascal G, Buraschi S, Iozzo R Proc Natl Acad Sci U S A. 2024; 121(18):e2317760121.

PMID: 38652741 PMC: 11067011. DOI: 10.1073/pnas.2317760121.


Global impact of proteoglycan science on human diseases.

Xie C, Schaefer L, Iozzo R iScience. 2023; 26(11):108095.

PMID: 37867945 PMC: 10589900. DOI: 10.1016/j.isci.2023.108095.


Decorin evokes reversible mitochondrial depolarization in carcinoma and vascular endothelial cells.

Neill T, Xie C, Iozzo R Am J Physiol Cell Physiol. 2022; 323(5):C1355-C1373.

PMID: 36036446 PMC: 9602711. DOI: 10.1152/ajpcell.00325.2022.


References
1.
Leygue E, Snell L, Dotzlaw H, Troup S, Murphy L, Roughley P . Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol. 2000; 192(3):313-20. DOI: 10.1002/1096-9896(200011)192:3<313::AID-PATH694>3.0.CO;2-B. View

2.
Zhang Z, Li X, Liu Y, Zhang X, Li Y, Xu W . Recombinant human decorin inhibits cell proliferation and downregulates TGF-beta1 production in hypertrophic scar fibroblasts. Burns. 2007; 33(5):634-41. DOI: 10.1016/j.burns.2006.08.018. View

3.
Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

4.
Van Bockstal M, Lambein K, Gevaert O, de Wever O, Praet M, Cocquyt V . Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast. Histopathology. 2013; 63(4):520-33. DOI: 10.1111/his.12188. View

5.
Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View